Sri/surgical Express, Inc. (STRC) Misses Q4 EPS by 4c

Sri/surgical Express, Inc. (NASDAQ: STRC) reported Q4 EPS of ($0.11), $0.04 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.35 million.

Sarcos ended the year with $217 million in unrestricted cash and cash equivalents on its balance sheet. An increase from $34 million at the end of 2020 due to the proceeds from the company’s business combination in September.

For earnings history and earnings-related data on Sri/surgical Express, Inc. (STRC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c